TGFB1 and neoplasm: Mechanistically, TGF−β binds TGFβRII on NK cells, activating SMAD2/3, which downregulates NKG2D and perforin expression; tumor-derived adenosine acts via A2A receptors to activate PKA signaling, suppressing NK metabolism and granule release (46–48).